Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel
NASDAQ:SCNX

Scienture 3/30/2026 Earnings Report

Scienture logo
$0.40 -0.02 (-5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 +0.00 (+0.50%)
As of 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Scienture EPS Results

Actual EPS
-$1.76
Consensus EPS
-$0.28
Beat/Miss
Missed by -$1.48
One Year Ago EPS
N/A

Scienture Revenue Results

Actual Revenue
($0.17) million
Expected Revenue
$0.49 million
Beat/Miss
Missed by -$654.70 thousand
YoY Revenue Growth
N/A

Scienture Announcement Details

Quarter
Date
3/30/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Scienture's next earnings date is estimated for Monday, May 11, 2026, based on past reporting schedules.

Conference Call Resources

Scienture Earnings Headlines

Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
May 7 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289973/0/en/scienture-secures-11-0-million-in-non-dilutive-debt-financing-to-accelerate-growth-of-approved-product-portfolio-and-advancement-of-r-d-pipeline.html
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
May 6 at 8:05 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/06/3288791/0/en/scienture-announces-third-patent-grant-for-arbli-losartan-potassium-oral-suspension-strengthening-long-term-market-exclusivity-through-2041.html
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software stocks two months before they crashed this year. Now, he's warning that one AI lab's breakthrough could CRASH the Nasdaq while igniting a $500 trillion wealth transfer. He's found a little-known $40 "pre-IPO backdoor" into the private startup behind this economic sea change.tc pixel
May 8 at 1:00 AM  |  Chaikin Analytics (Ad)
Scienture Holdings Secures $11.4 Million Structured Financing Deal
May 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scienture-holdings-secures-11-4-million-structured-financing-deal?utm_source=marketbeat.com&utm_medium=referral
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
April 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scienture-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-requirement-1036024553
Scienture Holdings, Inc. Receives Additional 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement
April 15, 2026  |  quiverquant.comQ
See More Scienture Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email.

About Scienture

Scienture (NASDAQ:SCNX) engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

View Scienture Profile
Earnings Tools